Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

5-HT2A receptor deficiency alters the metabolic and transcriptional, but not the behavioral, consequences of chronic unpredictable stress.

Jaggar M, Weisstaub N, Gingrich JA, Vaidya VA.

Neurobiol Stress. 2017 Jun 5;7:89-102. doi: 10.1016/j.ynstr.2017.06.001. eCollection 2017 Dec.

2.

Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.

de Sousa RT, Loch AA, Carvalho AF, Brunoni AR, Haddad MR, Henter ID, Zarate CA, Machado-Vieira R.

Neuropsychopharmacology. 2017 Mar;42(4):787-800. doi: 10.1038/npp.2016.149. Epub 2016 Aug 11. Review.

PMID:
27510426
3.

BDNF Val66Met Genotype Interacts With a History of Simulated Stress Exposure to Regulate Sensorimotor Gating and Startle Reactivity.

Notaras MJ, Hill RA, Gogos JA, van den Buuse M.

Schizophr Bull. 2017 May 1;43(3):665-672. doi: 10.1093/schbul/sbw077.

PMID:
27262112
4.

Single-Nucleotide Polymorphism of the FKBP5 Gene and Childhood Maltreatment as Predictors of Structural Changes in Brain Areas Involved in Emotional Processing in Depression.

Tozzi L, Carballedo A, Wetterling F, McCarthy H, O'Keane V, Gill M, Morris D, Fahey C, Meaney J, Frodl T.

Neuropsychopharmacology. 2016 Jan;41(2):487-97. doi: 10.1038/npp.2015.170. Epub 2015 Jun 16.

5.

Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):26S-40S.

6.

GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.

Kawaguchi DM, Glatt SJ.

Pharmacogenomics. 2014 Aug;15(11):1451-9. doi: 10.2217/pgs.14.96.

7.

Towards the clinical implementation of pharmacogenetics in bipolar disorder.

Salloum NC, McCarthy MJ, Leckband SG, Kelsoe JR.

BMC Med. 2014 May 30;12:90. doi: 10.1186/1741-7015-12-90.

8.

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Fabbri C, Porcelli S, Serretti A.

Can J Psychiatry. 2014 Feb;59(2):62-75. Review.

9.

Hypothesis of the neuroendocrine cortisol pathway gene role in the comorbidity of depression, type 2 diabetes, and metabolic syndrome.

Gragnoli C.

Appl Clin Genet. 2014 Apr 1;7:43-53. doi: 10.2147/TACG.S39993. eCollection 2014. Review.

10.

Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Reynolds GP, McGowan OO, Dalton CF.

Br J Clin Pharmacol. 2014 Apr;77(4):654-72. doi: 10.1111/bcp.12312. Review.

11.

Mechanisms of antidepressant resistance.

El-Hage W, Leman S, Camus V, Belzung C.

Front Pharmacol. 2013 Nov 22;4:146. doi: 10.3389/fphar.2013.00146. Review.

12.

A pilot study evaluating genetic and environmental factors for postpartum depression.

El-Ibiary SY, Hamilton SP, Abel R, Erdman CA, Robertson PA, Finley PR.

Innov Clin Neurosci. 2013 Sep;10(9-10):15-22.

13.

No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression.

Serretti A, Fabbri C, Pellegrini S, Porcelli S, Politi P, Bellino S, Menchetti M, Mariotti V, Demi C, Martinelli V, Cappucciati M, Bozzatello P, Brignolo E, Brambilla P, Pae CU, Balestrieri M, De Ronchi D.

Psychiatry Investig. 2013 Jun;10(2):180-9. doi: 10.4306/pi.2013.10.2.180. Epub 2013 May 30.

14.

Epigenetic Modulation of Mood Disorders.

Archer T, Oscar-Berman M, Blum K, Gold M.

J Genet Syndr Gene Ther. 2013 Feb 11;4(120). pii: 1000120.

15.

Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders.

Lester KJ, Eley TC.

Biol Mood Anxiety Disord. 2013 Feb 7;3(1):4. doi: 10.1186/2045-5380-3-4.

16.

FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2013 Mar;23(3):156-66. doi: 10.1097/FPC.0b013e32835dc133.

17.
18.

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM.

Neuropsychopharmacology. 2013 Feb;38(3):377-85. doi: 10.1038/npp.2012.191. Epub 2012 Sep 19.

19.

Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Hodgson K, Mufti SJ, Uher R, McGuffin P.

Genome Med. 2012 Jun 27;4(6):52. doi: 10.1186/gm351.

20.

Glucocorticoid-induced loss of DNA methylation in non-neuronal cells and potential involvement of DNMT1 in epigenetic regulation of Fkbp5.

Yang X, Ewald ER, Huo Y, Tamashiro KL, Salvatori R, Sawa A, Wand GS, Lee RS.

Biochem Biophys Res Commun. 2012 Apr 13;420(3):570-5. doi: 10.1016/j.bbrc.2012.03.035. Epub 2012 Mar 16.

Supplemental Content

Support Center